Provided by Tiger Trade Technology Pte. Ltd.

Trump Concept

3,291.54
+18.240.56%
Number of Gainers:11
Number of Losers:18
Number of Flat:2
PE:- -
High:3,295.88
Open:3,271.77
Low:3,257.07
Close:3,273.30
Volume:329.46M
Turnover:51.26B
Market Cap:6.23T
Float Cap:5.50T

Loading ...

Strategy - Purchased 4,603 BTC for $369.70 Mln Between Aug 24-30, 2026 - SEC Filing

THOMSON REUTERS
·
Yesterday

Pentagon Signs 7-Year Deals to Increase Missile Production

Reuters
·
Yesterday

Pentagon Makes 7-Year Agreements with General Dynamics and Lockheed Martin to Triple Pac-3 and Quadruple Thaad Production

THOMSON REUTERS
·
Yesterday

Dick’s Sporting Goods to Join Goldman Sachs Global Consumer and Retail Conference Fireside Chat

Reuters
·
Yesterday

Next up for Tesla's Self-Driving Tech: Potholes

Dow Jones
·
Yesterday

Eli Lilly's Psoriasis Drug Trial Shows Sustained Positive Results

Dow Jones
·
Yesterday

Foreign Banks Applaud China's Fresh Real Estate Overhaul, Marking the Most Substantial Housing Reform in Nearly Three Decades

Deep News
·
Yesterday

Riot Platforms (RIOT) Gets a Buy from Bernstein

TIPRANKS
·
Yesterday

U.s. Stocks on the Move-Pinterest, Intel, Slb

Reuters
·
Yesterday

The Stock Market Rally is About to Face Its Biggest Test

Dow Jones
·
Yesterday

Bernstein Sticks to Their Hold Rating for MARA Holdings (MARA)

TIPRANKS
·
Yesterday

Moonshot AI seeks up to 30% revenue share from major cloud providers for its Kimi models

Deep News
·
Yesterday

Does Adding Qualcomm’s Akash Palkhiwala to the Board Sharpen Applied Materials’ AI Strategy Narrative (AMAT)?

Simply Wall St.
·
Yesterday

Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What it Means for the Stock.

Dow Jones
·
Yesterday

AECOM Named Design Partner for Freeway Project in New Zealand

MT Newswires Live
·
Yesterday

Eli Lilly announces 52-week results from TOGETHER-PsO, TOGETHER-PsA

TIPRANKS
·
Yesterday

Model YL rear suspension failures plague owners as Tesla juggles record deliveries with slumping profits

Deep News
·
Yesterday

Eli Lilly - Taltz and Zepbound Lead to Deeper Improvements in Systemic Inflammation in Both Trials

THOMSON REUTERS
·
Yesterday

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Showed Improved and Durable Efficacy at One Year in Adults with Psoriatic Disease and Obesity

THOMSON REUTERS
·
Yesterday

Eli Lilly - Taltz and Zepbound Maintain or Improve Disease Activity at Week 52 Versus Taltz Alone

THOMSON REUTERS
·
Yesterday